Chemistry:PL-6983
| Clinical data | |
|---|---|
| Routes of administration | Subcutaneous injection |
| Identifiers | |
| CAS Number | |
PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.[1][2] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[1][2] The drug has reportedly been in pre-clinical development for all medical indications since 2008.[3] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[4] The chemical structure of PL-6983 has yet to be made public.
See also
References
- ↑ 1.0 1.1 1.2 "Opportunities for intervention in HSDD". The Journal of Family Practice 58 (7 Suppl Hypoactive): S26–30. July 2009. PMID 19825316. http://www.oncologypractice.com/fileadmin/jfp_archive/pdf/5807JFP_DIMEsupplv2.pdf. Retrieved 2015-05-14.
- ↑ 2.0 2.1 2.2 100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy. Jones & Bartlett Publishers. 25 October 2010. pp. 120–. ISBN 978-1-4496-1936-7. https://books.google.com/books?id=poiGbNuPj9sC&pg=PA120.
- ↑ "Research programme: sexual dysfunction therapy - Palatin Technologies". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800028349.
- ↑ "Palatin Technologies - PL-6983 for Female Sexual Dysfunction". 2015-05-26. http://www.palatin.com/products/6983.asp.
External links
- PL-6983 for Sexual Dysfunction - Palatin Technologies
- PL-6983 for Female Sexual Dysfunction - Palatin Technologies
- Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma - Genetic Engineering and Biotechnology News
- Research Programme: Sexual Dysfunction Therapy (PL-6983) - Palatin Technologies - AdisInsight
- How Sildenax Works? Composition & Benefits of Sildenax - Nutri Medi
- How Medicines Work To Improve Potency - Vera Farmacia
{{Navbox
| name = Sexual dysfunction pharmacotherapies | title = Sexual dysfunction pharmacotherapies | state = autocollapse | bodyclass = hlist | listclass = hlist
| group1 = Dopamine agonists | list1 =
- Apomorphine
- Cabergoline
- Lisuride
- Pergolide
- Piribedil
- Pramipexole
- Quinagolide
- Ropinirole
- Rotigotine
- Terguride
| group2 = Melanocortin agonists | list2 =
| group3 = PDE5 inhibitors | list3 =
- Acetildenafil
- Aildenafil
- Avanafil
- Icariin
- Lodenafil
- Mirodenafil
- Nitrosoprodenafil
- Sildenafil
- Sulfoaildenafil
- Tadalafil
- Udenafil
- Vardenafil
| group4 = Sex steroids | list4 =
- Androgens (e.g., [[testosterone, methyltestosterone, other anabolic steroids)
- Estrogens (e.g., [[estradiol, ethinylestradiol, conjugated equine estrogens (Premarin))
- Progestogens (e.g., [[progesterone, progestins)
- Mixed (e.g., tibolone)
| group5 = Others | list5 =
- Afrodor (acecarbromal, quebracho, vitamin E)
- Alkyl nitrites
- Alprostadil
- Amantadine
- Bupropion
- Buspirone
- Cyproheptadine
- Dapoxetine
- Flibanserin
- Mirtazapine
- Moxisylyte
- Oxytocin
- Papaverine
- Phentolamine
- Psychostimulants (e.g., amphetamines, cocaine, methylphenidate)
- Rauwolscine (Rauvolfia)
- Trazodone
- Yohimbine (Yohimbe)
| below =
}}
 |  |
